Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Paulina Selaru
Sign up to set email alerts
55
Publications
2,591
Citation Statements Received
1,150
Citation Statements Given
How they've been cited
3,891
84
2,501
6
How they cite others
1,264
30
1,115
5
Affiliations
Pfizer (United States)
,
Peter MacCallum Cancer Centre
Publications
Order By: Most citations
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Shaw
1
,
Yeap
2
,
Solomon
3
et al.
2011
The Lancet Oncology
Abstract
Show
894
13
553
2
Get access via publisher
Add to collection
Cite
Clinical Experience With Crizotinib in Patients With Advanced
ALK
-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
Costa
1
,
Shaw
2
,
Ou
3
et al.
2015
JCO
Abstract
Show
615
10
455
2
Get access via publisher
Add to collection
Cite
Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
Socinski
1
,
Novello
2
,
Brahmer
3
et al.
2008
JCO
Abstract
Show
311
15
188
0
Get access via publisher
Add to collection
Cite
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
Ou
1
,
Janne
2
,
Bartlett
3
et al.
2014
Annals of Oncology
Abstract
Show
213
6
167
0
Get access via publisher
Add to collection
Cite
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced
ALK
-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014
Solomon
1
,
Cappuzzo
2
,
Felip
3
et al.
2016
JCO
Abstract
Show
273
10
161
2
Get access via publisher
Add to collection
Cite
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer
Wu
1
,
Lü
2
,
Lü
3
et al.
2018
Journal of Thoracic Oncology
Abstract
Show
194
7
158
0
Get access via publisher
Add to collection
Cite
A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer
Haura
1
,
Ricart
2
,
Larson
3
et al.
2010
Abstract
Show
234
3
159
0
Get access via publisher
Add to collection
Cite
Acute Hemodynamic Effects of Conivaptan, a Dual V
1A
and V
2
Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure
Udelson
1
,
Smith
2
,
Hendrix
3
et al.
2001
Circulation
Abstract
Show
343
1
145
0
Get access via publisher
Add to collection
Cite
1
2
3
4